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Introduction: Histological subtype is an established prognostic
factor in malignant pleural mesothelioma (MPM). We retrospec-
tively investigated the accuracy of classifying histological subtype
on diagnostic biopsies and examined the impact of different diag-
nostic procedures on the outcome.
Methods: Consecutive patients with histologically confirmed MPM
who underwent extrapleural pneumonectomy (EPP) from 1994 to
2009 were included. Patient records were reviewed, and the initial
diagnoses of histological subtype were obtained. The archival EPP
specimens were reviewed by a panel of pathologists. The histolog-
ical subtype obtained at review was compared with the initial
diagnosis.
Results: Eighty-five patients underwent EPP. Two patients achieved
a pathological complete response after neoadjuvant chemotherapy,
leaving 83 patients to be included in this review. Different diagnos-
tic methods were used before EPP: 81% thoracoscopy; 7% thora-
cotomy; 11% computed tomography-guided procedure; and 1%
other. Patients determined to have an epithelial subtype (n  64) at
EPP were diagnosed correctly at initial diagnostic biopsy in 84% of
cases, whereas patients considered to have a biphasic subtype (n 19)
at EPP were diagnosed correctly at diagnostic biopsy in 26% of
cases. The sensitivity and specificity of diagnostic biopsy for epi-
thelial MPM was 93% and 31%, respectively. The overall subtype
misclassification rate was 20%. Biopsy by thoracotomy was most
accurate in subtype classification (83%) compared with thoracos-
copy (74%) and computed tomography-guided procedure (44%).
Conclusions: The determination of histological subtype from a
diagnostic biopsy is difficult due to sampling error, but an adequate
specimen obtained from surgical biopsy increases the accuracy of
subtype classification compared with radiological-guided biopsies.
Key Words: Malignant pleural mesothelioma, Epithelial mesothe-
lioma, Biphasic mesothelioma, Diagnosis.
(J Thorac Oncol. 2011;6: 602–605)
Malignant pleural mesothelioma (MPM) is an invariablyfatal, asbestos-related malignancy arising from the me-
sothelium, a membrane lining the serosal cavities.1 Because
of the long latency period between asbestos exposure and
development of MPM,2 and the continued widespread use of
asbestos in industrializing countries in Asia,3 MPM will
remain a worldwide health issue for many decades to come.
Despite suspicious clinical symptoms, a typical chest
x-ray appearance, or computed tomography (CT) findings
suggestive of a unilateral pleural effusion or pleural thicken-
ing, even when accompanied by a history of asbestos expo-
sure, the definitive diagnosis of MPM cannot be made with-
out a tissue diagnosis. At times, MPM may be diagnosed by
cytologic examination of the pleural effusion in combination
with characteristic radiological appearances and appropriate
follow-up; however, the results are often equivocal, or insuf-
ficient material is obtained to provide a definitive diagnosis.
Therefore, definitive histologic diagnosis by radiological-
guided core biopsy, video-assisted thoracoscopic biopsy, or
open pleural biopsy is often required.
The World Health Organization classification of tu-
mors of the lung and pleura4 recognizes three major
subtypes of MPM: epithelial, sarcomatoid, and biphasic.
Accurate histological subtyping is important, as histolog-
ical subtype is a validated prognostic factor. Survival of
patients with epithelial tumors is better than that of pa-
tients with nonepithelial tumors.5–7
Some clinicians believe that only patients with epithe-
lial subtype should be eligible for extrapleural pneumonec-
tomy (EPP), as the natural history of the disease does not
seem to be altered by radical surgery in patients with biphasic
or sarcomatoid mesothelioma.8,9 Hence, accurate subtyping
before radical surgery is paramount. Nevertheless, because of
heterogeneity of MPM, sampling errors can affect relatively
small diagnostic biopsies, and accurate subtyping may not
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always be feasible, even when the biopsies are obtained by
thoracoscopy.10,11
Although it is widely accepted that diagnostic biopsies
by video-assisted thoracoscopy or thoracotomy are more
likely to provide sufficient material for accurate histologi-
cal diagnosis of mesothelioma than core or closed pleural
biopsies on fine needle aspirate,12 it is not known whether
this approach provides greater accuracy in ascertaining the
histological subtype compared with other less invasive
procedures.
The experience of our group with EPP since 1994 has
allowed a comparison between subtyping of the initial diag-
nostic biopsy and that of the final EPP specimen.13 In this
study, we have examined the accuracy of subtyping on biopsy
samples obtained by thoracoscopy, thoracotomy, or a CT-
guided approach using the final diagnosis by a review panel
as the gold standard. In addition, we have explored the
accuracy of different biopsy procedures on the diagnosis.
MATERIALS AND METHODS
Eighty-five consecutive patients with MPM who under-
went EPP at Royal Prince Alfred and Strathfield Private
Hospitals, Sydney, Australia, were included in the study. For
each patient, the operative notes, outpatient records, and
pathology reports from the medical charts and electronic
records were reviewed in full. The initial assessment of the
subtype was derived from the diagnostic pathology report.
Seventy-eight archival EPP specimens were resectioned,
stained with calretinin (Invitrogen), D2-40 (Signet), BG-8
(Signet), and CD15 (Dako), and reviewed by pathologists
with substantial experience in MPM (K.L. and S.K.) inde-
pendently. The total number of sections had not been re-
corded for all EPP specimens, but where data were available
(n  66), the median number of sections that resulted from
each EPP procedure was 23, with a range from 12 to 57.
Pathologists were blinded to the original subtype diagnosis,
and discrepancy in assessment between the pathologists was
reviewed by the most senior pathologist (D.W.H.).
Histological Subtype Assignment
The histological subtypes were assigned in accordance
with World Health Organization criteria and recommenda-
tions. The presence of an epithelial component was assessed
by the presence of an “epithelioid” cytology in terms of
rounded to polygonal neoplastic cells, usually with at least
focal tubular, papillary, or trabecular patterns for the cells, or
their disposition as sheets of cells, whereas a sarcomatoid
component was assessed by the presence of nonepithelioid
spindle-cell tissue, usually resembling fibrosarcoma or ma-
lignant fibrous histiocytoma. On rare occasions, it may be
difficult to ascertain whether the cells are epithelial or mes-
enchymal (histiocytoid) in character, and such mesotheliomas
have been designated as “transitional”: in this circumstance,
classification as either epithelioid or sarcomatoid tissue may
be facilitated by a transition to adjacent more obvious epi-
thelioid or sarcomatoid tissue, and by immunohistochemistry
(with absent or restricted labeling for/with mesothelial mark-
ers). There were no true “transitional” mesotheliomas in our
series of cases.
A biphasic histological subtype was assigned only if
both subtypes (epithelial and sarcomatoid) were accounted
for more than 10% of cross-sectional area. The archival tissue
for the remaining five EPP specimens was unable to be
located, and the histological subtype was determined from the
pathology report.
This study was approved by the Human Research
Ethics Committees at the Sydney South West Area Health
Service—Concord Repatriation General Hospital Zone.
Statistical Analysis
Using the final histological subtype of the EPP speci-
men as the gold standard, the sensitivity, specificity, positive
predictive value, and negative predictive value were deter-
mined for the accuracy of the initial biopsy histological
subtype diagnosis. This analysis comprised only patients with
a pre-EPP diagnosis of an epithelial or a nonepithelial (bi-
phasic and sarcomatoid) subtype and excluded patients with-
out an initial subtype or a negative initial biopsy.
RESULTS
Patient Cohort
The median age of the 85 patients in the EPP cohort
was 58 years (range: 22–74). Eighty percent of patients were
men. Fifty-eight percent of patients had a right-sided EPP.
The initial pathological diagnoses were based on his-
tology in 91% of patients and in 9% on cytological exami-
nation of the pleural effusion or from the fine needle biopsy.
The diagnostic procedures that resulted in the diagnosis for
all 85 patients included thoracoscopy (81%), thoracotomy
(7%), CT-guided procedure (11%), and biopsy of a chest wall
nodule (1%). All 9% of cytological examination of the
pleural effusion resulted from a CT-guided procedures.
All but two patients had definitive pathological diag-
nosis of MPM before EPP. The two remaining patients
proceeded to EPP based on a highly suspicious pleural
aspirate (obtained by CT-guided needle).
Nineteen patients (22%) had preoperative therapy: 18
were treated with neoadjuvant chemotherapy, whereas one
was treated with concurrent chemoradiation. Two patients
attained a pathological complete response with the combina-
tion of a platinum and pemetrexed, limiting our study series
to 83 patients. Figure 1 demonstrates the flow diagram of our
study.
Comparison between Initial and Final
Histological Subtype
Table 1 demonstrates the relationship between the ini-
tial and final histological subtype diagnoses of resected
MPM. Of the 83 patients with MPM with residual tumor at
EPP, 64 (77%) had an epithelial MPM, whereas 19 (23%)
were found on review to have a biphasic MPM.
Among those 64 patients with an epithelial subtype at
EPP, 54 (84%) had been classified as epithelial on the basis of
the pre-EPP diagnosis, three (5%) were classified as biphasic,
one (2%) was classified as sarcomatoid, whereas classification
was not possible in six (9%) including the two patients with
suspicious cytology mentioned earlier in the text.
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Of the 19 patients diagnosed as biphasic MPM at final
review, 11 (58%) were initially classified as epithelial, five
(26%) as biphasic, and three (16%) were not classified.
The sensitivity and specificity of a diagnosis of epithe-
lial classification at the initial biopsy workup were 93% and
31%, respectively, with a positive predictive value of 83%
and a negative predictive value of 56%.
Accuracy of Subtype Classification from the
Diagnostic Methods
The accuracy of the histological subtype diagnosis after
a biopsy was 74% from a thoracoscopy; 83% after a biopsy
taken at thoracotomy; and 44% after a CT-guided procedure.
DISCUSSION
Accuracy of histological subtyping of MPM was re-
viewed in a single-center series of patients with MPM who
underwent EPP. We were able to demonstrate that in 17% of
patients initially diagnosed with an epithelial subtype, the
subtype identified in the large samples obtained at EPP was
found to be biphasic. Forty-four percent of the patients
initially diagnosed as nonepithelial subtype (biphasic or sar-
comatoid) were found to have epithelial subtype after EPP.
Surprisingly, the single patient who was diagnosed as having
a sarcomatoid MPM at the initial biopsy was found to have an
epithelial subtype after EPP. This represented a 20% misclas-
sification rate at initial biopsy, largely confirming the mis-
classification rates found by other groups.10,11
Our experience differed from that described in the two
previous reports,10,11 in that our diagnostic procedures were
not confined to thoracoscopy only as thoracotomy, and CT-
guided procedures were also used. This allowed us to also
focus on the effect of different ways to obtain biopsy material
and the accuracy of subtype classification.
Although pleural biopsy by thoracoscopy is often re-
quired to confirm the presence of MPM after other closed
biopsy attempts, there is no literature that compares the
impact of different diagnostic methods on the accuracy of
subtype classification of MPM. To diagnose the biphasic
subtype of MPM, the International Mesothelioma Panel ar-
bitrarily recommended the presence of at least 10% of either
an epithelial or a sarcomatous component by cross-sectional
area in the sections.4 Therefore, by definition, a mesothelioma
that consisted of a predominantly epithelial component with
less than 10% sarcomatoid component would be classified as
an epithelial mesothelioma. This may explain why there was
one patient with epithelial MPM who was thought to have
sarcomatoid subtype on the initial diagnostic biopsy. As a
result, adequate sampling is an important issue for accurate
subtype classification. Another possible explanation for the
discrepant histological subtyping between the diagnostic bi-
opsy and EPP specimen could be the difficult distinction
between a true sarcomatoid component and a cellular desmo-
plastic response on a small biopsy specimen.
This study confirms that the diagnostic accuracy of the
histological subtyping is better in biopsies obtained by tho-
racotomy (83%) or thoracoscopy (74%), compared with bi-
opsy by CT-guided procedures (44%), although we acknowl-
edge the limitation of the small number of patients in the
subset who had CT-guided procedures (n  9), which may
limit the interpretation of these results. Thus, the adequacy of
tissue sampling is likely to be important to obtain an accurate
histological subtype classification.
If an initial nonepithelial subtype diagnosis had served
as an exclusion criterion, four patients would have been
excluded from EPP due to sampling error. Conversely, 17%
of patients with an epithelial subtype on initial biopsy had
nonepithelial classification on the final specimen. This mis-
classification rate is relatively high, and on the basis of low
negative predictive value seen in our study, we caution using
subtype as a selection criterion for EPP, unless a large
diagnostic biopsy specimen was obtained and the histological
subtype assignment was deemed accurate.
In conclusion, an adequate pleural biopsy increases the
accuracy of histological subtyping. In addition, this series un-
derscores the inherent problems of sampling errors and inaccu-
rate histological subtyping due to inadequacy of samples.
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83 pathologically confirmed MPM
• 69 thoracoscopy
• 4 thoracotomy
• 1 other
• 7 CT-guided procedures
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85 underwent EPP
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FIGURE 1. Study flow diagram.
TABLE 1. Comparison between Initial and Final Histological
Subtype in Malignant Pleural Mesothelioma Patients
Undergoing Extrapleural Pneumonectomy (n  83)
Initial Diagnostic Biopsy
TotalEpithelial Nonepitheliala
Subtype
Not
Classified Negative
Subtype from
EPP
Epithelial 54 4 4 2 64
Biphasic 11 5 3 0 19
a Nonepithelial consists of biphasic and sarcomatoid mesothelioma.
EPP, extrapleural pneumonectomy.
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